<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232332</url>
  </required_header>
  <id_info>
    <org_study_id>PR-JSZX-2019015F</org_study_id>
    <nct_id>NCT04232332</nct_id>
  </id_info>
  <brief_title>The Phase I Study of Recombinant Human Nerve Growth Factor Injection</brief_title>
  <official_title>The Phase I Study of Recombinant Human Nerve Growth Factor Injection in Healthy Chinese Volunteers on Safety, Tolerability and Pharmacokinetics: Randomized, Double-blind, Placebo-controlled, Single / Multiple Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, single/multiple dose study of recombinant
      human nerve growth factor injection in healthy Chinese volunteers on safety, tolerability and
      pharmacokinetics
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single / multiple dose trial.
      recombinant human nerve growth factor injection in healthy Chinese volunteers on safety, and
      pharmacokinetics.The volunteers will be given the drug by intramuscular injection. The main
      purpose of this trial is to investigate the safety, tolerability , pharmacokinetics and
      immunogenicity of Chinese healthy volunteers after intramuscular injection of recombinant
      human nerve growth factor injection, to provide a safe dose range for subsequent clinical
      trials, as well as a safe and reasonable drug delivery program.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Single dose: 28 days / Multiple dose: 34 days</time_frame>
    <description>Record the number of participants with abnormal laboratory values and/or adverse events,calculate frequency and percentage based on correlation with the investigational drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under curve (AUC) after injection of single dose/multiple dose</measure>
    <time_frame>Single dose: 24 hours / Multiple doses: 8 days</time_frame>
    <description>To measure the drug concentration in blood samples which collected after injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax after injection of single dose/multiple dose</measure>
    <time_frame>Single dose: 24 hours / Multiple doses: 8 days</time_frame>
    <description>To measure the drug concentration in blood samples which collected after injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax after injection of single dose/multiple dose</measure>
    <time_frame>Single dose: 24 hours / Multiple doses: 8 days</time_frame>
    <description>To measure the drug concentration in blood samples which collected after injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 after injection of single dose/multiple dose</measure>
    <time_frame>Single dose: 24 hours / Multiple doses: 8 days</time_frame>
    <description>To measure the drug concentration in blood samples which collected after injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With anti-drug antibodies</measure>
    <time_frame>Single dose: 28 days / Multiple dose: 34 days</time_frame>
    <description>Percentage of participants with treatment-emergent positive anti-drug antibodies was summarized by treatment group.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Injury of Optic Nerve</condition>
  <arm_group>
    <arm_group_label>3.75μg (pre test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15μg single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30μg single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45μg single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60μg single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75μg single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90μg single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30μg multiple dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The dosage will be adjusted according to the actual situation of the trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60μg multiple dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The dosage will be adjusted according to the actual situation of the trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human nerve growth factor injection,experimental</intervention_name>
    <description>Intramuscular injection once on the first day according to dose requirements</description>
    <arm_group_label>3.75μg (pre test)</arm_group_label>
    <arm_group_label>7.5μg</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human nerve growth factor injection,single dose</intervention_name>
    <description>Intramuscular injection once on the first day according to dose requirements</description>
    <arm_group_label>15μg single dose</arm_group_label>
    <arm_group_label>30μg single dose</arm_group_label>
    <arm_group_label>45μg single dose</arm_group_label>
    <arm_group_label>60μg single dose</arm_group_label>
    <arm_group_label>75μg single dose</arm_group_label>
    <arm_group_label>90μg single dose</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human nerve growth factor injection,multiple dose</intervention_name>
    <description>Intramuscular injection once daily for 7 days according to dose requirements</description>
    <arm_group_label>30μg multiple dose</arm_group_label>
    <arm_group_label>60μg multiple dose</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18-45 years old, including boundary value;

          2. The body weight meets the standard, the body weight of male volunteers is not less
             than 50kg, the body weight of female volunteers is not less than 45kg, the body mass
             index is in the range of 19-24kg / m2, the body mass index = body weight (kg) / height
             (M2);

          3. volunteers participated in the study voluntarily and signed informed consent.

        Exclusion Criteria:

          1. Take any prescription or over-the-counter drugs within 2 weeks before screening;

          2. Those who have been vaccinated within 3 months before screening;

          3. Those who participated in any clinical trial within 3 months before screening;

          4. Those who lost blood or donated more than 200 ml blood within 4 weeks before screening
             or who intend to donate blood during the study or within 4 weeks after the end of the
             study;

          5. Diseases with clinical significance within 2 weeks before screening;

          6. Those who had major surgery, trauma or hospitalization within 6 months before
             screening;

          7. There is tattoo or other influence on the injection site to observe the skin
             condition;

          8. Patients with history of central nervous system, mental system, cardiovascular system,
             urinary system, digestive system, respiratory system, metabolism system, blood system,
             immune system, endocrine system and skeletal muscle system may endanger the safety of
             the subjects or affect the research results according to the judgment of the
             researchers;

          9. There is a significant history of allergy in clinic, especially the history of drug
             allergy, especially the allergy to any component of zx1305 injection;

         10. The five items of hepatitis B (hepatitis B surface antigen, hepatitis B surface
             antibody, hepatitis B e antigen, hepatitis B e antibody, hepatitis B core antibody),
             hepatitis C antibody, syphilis specific antibody or AIDS joint test have clinical
             significance;

         11. It is suspected that there is alcohol dependence, and the average alcohol intake in
             the first half year of screening is more than 2 units per day (1 unit = 10ml alcohol,
             i.e. 1 unit = 200ml beer with 5% alcohol or 25ml spirits with 40% alcohol or 83ml wine
             with 12% alcohol) or the alcohol test is positive;

         12. Those who smoked more than 5 cigarettes per day in the first half year of screening;

         13. Those who had a history of drug abuse or had taken drugs within one year before
             screening, or who were positive in urine test of ketamine, morphine, methamphetamine,
             dimethyldioxygoamphetamine and tetrahydrocannabinolic acid;

         14. Women who are positive in pregnancy, lactation, blood pregnancy or who have not taken
             effective contraceptive measures in the last month, and men or women who are not
             willing to take effective non drug contraceptive measures during the whole trial
             period and who are not willing to take effective contraceptive measures within one
             year after the end of the trial;

         15. The condition of peripheral venous access is poor (difficult to collect blood);

         16. There are other reasons that the researchers think should not be selected.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Wu</last_name>
    <phone>010-58268422</phone>
    <email>bjtrec@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Zhang</last_name>
    <phone>025-58310595</phone>
    <email>Zhang.Yi@xintrum.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Wu</last_name>
      <phone>010-58268422</phone>
      <email>bjtrec@126.com</email>
    </contact>
    <investigator>
      <last_name>Xiuli Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 12, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

